The combination of relatlimab, a monoclonal antibody targeting LAG-3 (BMS-986016), and nivolumab, a monoclonal antibody against PD-1, has demonstrated significant therapeutic efficacy in melanoma patients who have previously shown resistance to anti-PD-1/PD-L1 treatments (130). This evidence concerns the gene PDCD1 and melanoma.